The goal of this project is to develop soft kinase inhibitors for IBD to EDC status, to achieve in vivo validation in relevant animal models, Amakem's soft kinase platform for further validate potential IBD medications, Amakem's patent portfolio from to expand and more disease-relevant knowledge about the role of certain biochemical mechanisms to gain involved in the pathophysiology of IBD. In vivo tests will also be used to determine whether Amakem's platform, making local active inhibitors of intracellular targets can be validated for diseases of the gastrointestinal tract